Search results for "Injection"

showing 10 items of 920 documents

Retrograde transport of sodium selenite and intracellular injection of micro-ruby: a combined method to describe the morphology of zinc-rich neurones.

2003

Abstract Zinc is found in synaptic vesicles in a large number of glutamatergic systems. Its involvement in neurotransmission and neurological disorders has been suggested. There are methods for tracing these circuits, but they do not fill the dendritic tree. In this study, extracellular selenite injections in vivo were combined with intracellular injection of fluorochromes in fixed tissue to reveal the morphology of these zinc-rich neurones. Intraperitoneal and intracerebral injections of sodium selenite alone or intracerebral injections of selenite combined with bisbenzimide were made in the visual cortex of the rat in order to locate the somata of zinc-rich neurones. After 24 h of retrogr…

BisbenzimideMaleSilver StainingBiotinCell CountNeurotransmissionBiologySynaptic vesicleRats Inbred WKYchemistry.chemical_compoundSodium SeleniteBiocytinNeural PathwaysExtracellularAnimalsRats WistarVisual CortexNeuronsLucifer yellowMicroscopy ConfocalRhodaminesGeneral NeuroscienceDrug Administration RoutesLysineDextransSomatosensory CortexIontophoresisIsoquinolinesRatsNeuroanatomyZincnervous systemchemistryBiochemistryAxoplasmic transportBiophysicsInjections JetExtracellular SpaceIntracellularInjections IntraperitonealJournal of neuroscience methods
researchProduct

Is the nuclear status of an embryo an independent factor to predict its ability to develop to term?

2012

Objective To determine the prognostic impact of the embryo nuclear status at day 2 among other major morphologic parameters (first cleavage at day 1, number of blastomeres and anuclear fragmentation at day 2) on the birth rate. Design Retrospective study. Setting Hospital IVF department. Patient(s) Women undergoing 1,629 day 2 transfers of 2,732 embryos from May 2006 to November 2008. Intervention(s) Four groups according to the embryo nuclear status. Main Outcome Measure(s) Implantation, miscarriage, and birth rates. Result(s) Univariate analysis indicated significantly higher birth rates when all blastomeres were mononucleated (15.0%) compared with embryos with not all blastomeres mononuc…

Blastomeresmedicine.medical_specialtyMultivariate analysisPregnancy RateEmbryonic DevelopmentFertilization in VitroBiologyCleavage (embryo)MiscarriageBirth ratePredictive Value of TestsPregnancymedicineHumansEmbryo ImplantationSperm Injections IntracytoplasmicRetrospective StudiesCell NucleusGynecologyUnivariate analysisObstetrics and GynecologyEmbryoBlastomerePrognosismedicine.diseaseAbortion SpontaneousBlastocystReproductive MedicineMultivariate Analysisembryonic structuresFemaleEmbryo qualityFertility and Sterility
researchProduct

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

2015

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive on…

Blood GlucoseCounselingMaleType 2 diabeteslaw.inventionBody Mass IndexRandomized controlled trialWeight losslawGlucagon-Like Peptide 1Weight managementSubcutaneousMedicine (all)ReducingNauseaGeneral MedicineMiddle AgedCombined Modality Therapy3. Good healthFemaletype 2 diabetesmedicine.symptomHumanmedicine.drugAdultDiarrheamedicine.medical_specialtyDiet ReducingInjections SubcutaneousInjections SubcutaneouPlaceboInjectionsDouble-Blind MethodInternal medicineWeight LossmedicineHumansHypoglycemic AgentsObesityExerciseHypoglycemic AgentLiraglutidebusiness.industryLiraglutidemedicine.diseaseWeight LoDietEndocrinologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidemiaAdult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Counseling; Diarrhea; Diet Reducing; Double-Blind Method; Exercise; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Nausea; Obesity; Weight Loss; Medicine (all)The New England journal of medicine
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Vinblastine-induced autophagocytosis: effects on liver glycogen

1983

The possible similarities of the mechanism by which vinblastine induces autophagocytosis in liver were compared with the known effects of glucagon in glucagon-induced autophagocytosis. A single intraperitoneal injection of vinblastine produced a wave of autophagocytosis in less than 0.5 h in mouse hepatocytes. Liver glycogen content decreases simultaneously and blood glucose first increased and then decreased below control values. Both liver cAMP concentration and the activity of glycogen phosphorylase remained unchanged. These findings provide evidence that the induction of autophagocytosis after vinblastine injection is not mediated by cAMP. The increased degradation of glycogen may occur…

Blood GlucoseMaleendocrine systemmedicine.medical_specialtyPhosphorylasesAutophagocytosismedicine.medical_treatmentIntraperitoneal injectionBiophysicsBiologyVinblastineBiochemistryGlucagonMicechemistry.chemical_compoundPhagocytosisStructural BiologycAMPInternal medicineAutophagyCyclic AMPGeneticsmedicineAnimalsMolecular BiologyGlycogendigestive oral and skin physiologyVinoblastineCell BiologyVinblastineMicroscopy ElectronEndocrinologyLiverchemistryGlycogenhormones hormone substitutes and hormone antagonistsmedicine.drugFEBS Letters
researchProduct

Treatment of Severe Reactive Hypoglycemia With a Somatostatin Analogue (SMS 201-995)

1990

• Reactive (or postprandial) hypoglycemia can sometimes represent a severe disorder refractory to conventional therapeutic measures. We present in this first individual trial, to our knowledge, that the administration of a somatostatin analogue (SMS 201 -995) may alleviate the severity of complaints and does not appear to be diabetogenic. The effects of the somatostatin analogue were documented in a 5-hour oral glucose tolerance test, where not only the glucose-induced and C-peptide rise was clearly attenuated, but also the blood glucose concentration did not fall low enough to induce hypoglycemic symptoms. ( Arch Intern Med. 1990;150:2401-2402)

Blood GlucoseMalemedicine.medical_specialtyInjections SubcutaneousHypoglycemiaOctreotideRefractoryInternal medicineInternal MedicinemedicineHumansInsulinOral glucose toleranceSevere disorderGlucose tolerance testReactive hypoglycemiaC-Peptidemedicine.diagnostic_testbusiness.industryGlucose Tolerance TestMiddle Agedmedicine.diseaseHypoglycemiaSomatostatin AnaloguePostprandialEndocrinologyFoodbusinessArchives of Internal Medicine
researchProduct

The effects of cold and glucagon on lipolysis, glycogenolysis and oxygen consumption in young chicks.

1973

Abstract 1. 1. To study the possible role of glucagon in avian thermoregulation the effects of cold exposure and glucagon on lipolysis, glycogenolysis and oxygen consumption were measured in young chicks. 2. 2. Cold exposure (+10°C) and glucagon injection (0·3 mg/kg, i.p. at +30°C) both caused a marked increase in the plasma FFA and a decrease in the liver glycogen content. 3. 3. It is suggested that glucagon possibly acts in the avian thermoregulation by producing at least lipolysis and glycogenolysis during cold exposure.

Blood Glucoseendocrine systemmedicine.medical_specialtyGlycogenolysisCold exposurechemistry.chemical_elementBiologyFatty Acids NonesterifiedGlucagonOxygenchemistry.chemical_compoundOxygen ConsumptionInternal medicinemedicineLipolysisAnimalsGlycogenGeneral MedicineThermoregulationGlucagonStimulation ChemicalLiver GlycogenCold TemperatureEndocrinologychemistryLiverDepression ChemicalGlucagon InjectionChickenshormones hormone substitutes and hormone antagonistsBody Temperature RegulationComparative biochemistry and physiology. A, Comparative physiology
researchProduct

Ambulatory Glucose Profile Applied to Flash Glucose Monitoring in Real Life: An Expert Opinion.

2016

The clinical benefits of real time continuous glucose monitoring (rtCGM) use have been well demonstrated in both CSII- and MDI-treated individuals in large clinical trials. However, recommendations for patient use of rtCGM in everyday life situations are lacking. This article provides guidance to clinicians and patients with type 1 diabetes (T1D) in effective use of rtCGM data, including glucose rate of change (ROC) arrows, for insulin dosing adjustments and other treatment decisions. The recommendations presented here are based on our own clinical experiences as endocrinologists, our personal experiences living with T1D using rtCGM, and findings from a recent survey of T1D patients who hav…

Blood Glucosemedicine.medical_specialtymultiple daily insulin injectionstype 1 diabetesEndocrinology Diabetes and MetabolismMonitoring ambulatoryBiomedical Engineeringflash glucose monitoringrate of changeMonitoring Ambulatory030209 endocrinology & metabolismBioengineeringglucose-monitoring systemMDI03 medical and health sciencesFlash (photography)0302 clinical medicineDiabetes mellitusBlood Glucose Self-MonitoringmedicineInternal MedicineIn real lifeambulatory glucose profile; diabetes; flash glucose monitoring; glucose-monitoring systems; glycemic control030212 general & internal medicineglucose-monitoring systemsIntensive care medicineambulatory glucose profileExpert TestimonyReview Articlesdiabetesbusiness.industryMedicine (all)Blood Glucose Self-MonitoringCSIImedicine.diseaseDiabetes Mellitus Type 1GlucosediabeteExpert opinioninsulin pumpAmbulatoryglucose profileglycemic controlcontinuous glucose monitoringMedical emergencybusinessJournal of diabetes science and technology
researchProduct

Combination of an allogenic and a xenogenic bone substitute material with injectable platelet-rich fibrin – A comparative in vitro study

2020

The aim of the in vitro study was a comparison of an allogenic (ABSM) and a xenogenic bone substitute material (XBSM) with and without injectable platelet-rich fibrin (ABSM-i-PRF & XBSM-i-PRF) on cell characteristics of human osteoblasts (HOB). Here, ABSM and XBSM (+ i-PRF = test; - i-PRF = control) were incubated with HOB for 3, 7 and 10 days. HOB viability, migration, proliferation and differentiation (RT-PCR on alkaline phosphatase (AP), bone morphogenetic protein 2 (BMP-2) and osteonectin (OCN)) were measured and compared between groups. At day 3, an increased viability, migration and proliferation was seen for ABSM-i-PRF. For viability and proliferation (days 7 and 10) and for mig…

Bone substituteBiomedical EngineeringPharmacologyFibrinCell LineInjectionsBiomaterials03 medical and health sciences0302 clinical medicineCell MovementPlatelet-Rich FibrinHumansIn vitro studyCell Proliferation030304 developmental biology0303 health sciencesOsteoblastsbiologyChemistryCell Differentiation030206 dentistrydigestive system diseasesPlatelet-rich fibrinIn vitroBone Substitutesbiology.proteinJournal of Biomaterials Applications
researchProduct

Plasma concentration following oral and intramuscular atropine in children and their clinical effects.

1997

In a paediatric population, we compared i.m. v oral atropine premedication to a control group without atropine and determined atropine plasma concentrations (APC). Forty-five children were randomly assigned to one of three groups. Group I received atropine, 20 micrograms.kg-1 i.m., 15 min prior to induction. Group II received atropine, 30 micrograms.kg-1 orally, group III received no atropine. APC (expressed as percent of muscarine-2 receptor subtype occupancy), heart rate, rectal temperature, and salivation were determined before atropine, and 15, 25, 45, 60, 90, 120 (no APC), and 150 min following atropine. Only 10-20% of the M2-cholinoceptors were occupied after oral atropine with a peak…

BradycardiaAtropineMalemedicine.medical_specialtyGroup iiAdministration OralMuscarinic AntagonistsInjections IntramuscularReceptor subtypeBody TemperatureHeart RateInternal medicineHeart rateMedicineHumansChildReceptor Muscarinic M2business.industryReceptors MuscarinicAtropineAnesthesiology and Pain MedicineEndocrinologyAnesthesiaChild PreschoolPediatrics Perinatology and Child HealthPlasma concentrationPremedicationFemalemedicine.symptombusinessSalivationPreanesthetic MedicationPaediatric populationmedicine.drugPaediatric anaesthesia
researchProduct